PTCHF — PureTech Health plc
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1782999 ·
Last close
$1.60
Market Cap
$388.74M
52W High
$1.92
52W Low
$1.56
ADV30
1,423
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 534,710,000 | 252,470,000 | 229,034,000 |
| Jun 2025 | — | — | — | — | 553,242,000 | 260,604,000 | 184,217,000 |
| Dec 2024 | — | — | — | — | 602,635,000 | 280,641,000 | 194,702,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-77,231,000
Inventory
—
Receivables
—
ST Investments
$24,829,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,659,000
EBITDA
$-96,830,000
Free Cash Flow
$-89,990,376
Enterprise Value
$296,881,856
Total Cash
$288,716,000
Total Debt
$203,256,000
Shares Out
243,418,190
Trailing EPS
$-0.46
Book Value
$1.29
ROE
-30.9%
ROA
-10.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,659,000 | -98,525,000 | -109,739,000 | 534,710,000 | 229,034,000 | — | -85,131,000 |
| Dec 2024 | 4,315,000 | -136,095,000 | 53,510,000 | 602,635,000 | 194,702,000 | — | -134,369,000 |
| Dec 2023 | 750,000 | -146,201,000 | -65,697,000 | 693,973,000 | 235,742,000 | — | -105,917,000 |
| Dec 2022 | 2,090,000 | -197,806,000 | -50,354,000 | 702,647,000 | 155,058,000 | — | -178,792,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $393.14M | $0.37 | — |
| ABEO | ABEONA THERAPEUTICS INC. | $397.83M | $6.98 | — |
| ENTA | ENANTA PHARMACEUTICALS INC | $398.37M | $13.70 | — |
| AVIR | Atea Pharmaceuticals, Inc. | $399.34M | $4.99 | — |
| AKBA | Akebia Therapeutics, Inc. | $375.56M | $1.40 | — |
News headlines (Yahoo Finance, 1h cache)
Celea Therapeutics secures $180m for Phase III SURPASS-IPF trial
2026-07-03 11:06 · Yahoo
A PureTech startup banks $180M for a new IPF drug
2026-07-02 11:04 · Yahoo
Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
2026-07-02 06:01 · Yahoo
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
2026-07-02 06:01 · Yahoo
PureTech Health: Results of Annual General Meeting
2026-06-10 17:14 · Yahoo
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
2026-06-09 06:00 · Yahoo
Seaport Therapeutics stock pops 17% on Nasdaq debut
2026-05-01 17:32 · Yahoo
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
2026-05-01 08:26 · Yahoo
PureTech Health H2 Earnings Call Highlights
2026-04-29 20:30 · Yahoo
PureTech Health plc (LON:PRTC) is favoured by institutional owners who hold 73% of the company
2026-01-03 09:18 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.